Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) have earned an average recommendation of “Hold” from the twenty-three analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $104.4211.
A number of analysts have recently issued reports on ZBH shares. Royal Bank Of Canada lifted their target price on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Truist Financial increased their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group lifted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research note on Monday, August 10th.
Read Our Latest Report on Zimmer Biomet
Zimmer Biomet Stock Down 0.6%
Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts forecast that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.
Hedge Funds Weigh In On Zimmer Biomet
Several large investors have recently made changes to their positions in ZBH. OMERS ADMINISTRATION Corp acquired a new position in Zimmer Biomet during the second quarter worth $922,000. Hsbc Holdings PLC bought a new stake in shares of Zimmer Biomet in the 2nd quarter worth approximately $35,417,000. PNC Financial Services Group Inc. increased its position in shares of Zimmer Biomet by 9.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares during the period. Morningstar Investment Management LLC boosted its stake in Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after buying an additional 40,610 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Zimmer Biomet by 257.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after buying an additional 24,748 shares during the period. Institutional investors own 88.89% of the company’s stock.
About Zimmer Biomet
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.
Read More
- Five stocks we like better than Zimmer Biomet
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
